Biocept, Inc. (BIOC)
| Market Cap | 25.73M |
| Revenue (ttm) | 61.25M |
| Net Income (ttm) | -2.82M |
| Shares Out | 16.90M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,034 |
| Open | 1.56 |
| Previous Close | 1.54 |
| Day's Range | 1.51 - 1.58 |
| 52-Week Range | 1.43 - 4.97 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 9.69 (+536.7%) |
| Earnings Date | May 18, 2022 |
About BIOC
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSC...
Financial Performance
In 2021, Biocept's revenue was $61.25 million, an increase of 123.04% compared to the previous year's $27.46 million. Losses were -$2.82 million, -84.14% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BIOC stock is "Buy." The 12-month stock price forecast is 9.69, which is an increase of 536.66% from the latest price.
News
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q f...
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purcha...
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 3...
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and c...
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
SAN DIEGO--(BUSINESS WIRE)---- $BIOC--Biocept to report 2021 fourth quarter and full year financial results on March 30, 2022.
Biocept Appoints Philippe Marchand as Chief Operating Officer
SAN DIEGO--(BUSINESS WIRE)--Biocept names Philippe Marchand as new Chief Operating Officer to oversee strategic business operations, including its CNSide CSF assay.
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Developme...
SAN DIEGO--(BUSINESS WIRE)--Biocept highlights CNSide assay's ability to aid clinical research efforts to improve treatment of metastatic cancers involving brain.
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interi...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim Presiden...
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
SAN DIEGO--(BUSINESS WIRE)--Biocept names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer.
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CLIA_Lab--Biocept has received more than 765,000 samples for RT-PCR COVID-19 testing since June 2020.
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?
Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company...
Biocept's CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that h...
SAN DIEGO--(BUSINESS WIRE)--SABCS Spotlight Presentation shows that Biocept's CNSide CSF assay identifies actionable HER2 mutations in metastatic breast cancer.
Quest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diag...
SECAUCUS, N.J. and SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics (NYS...
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
SAN DIEGO--(BUSINESS WIRE)--Biocept launches combined COVID-19 and influenza test to help patients and caregivers determine treatment decisions during peak flu season.
CORRECTING and REPLACING Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects...
SAN DIEGO--(BUSINESS WIRE)--Case series shows Biocept's CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.
Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in...
SAN DIEGO--(BUSINESS WIRE)--Case series shows Biocept's CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.
Biocept Reports Third Quarter 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended Septembe...
Study Shows Biocept's Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays i...
SAN DIEGO--(BUSINESS WIRE)--Published abstract shows Biocept's Switch-Blocker technology increases the sensitivity of liquid biopsy assays for detecting rare cancer mutations.
Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nin...
Biocept to Present at the LD Micro Main Event on October 13
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #LD_Micro--Biocept to present at LD Micro Main Event
Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients
Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain or spinal cord. Between 10% an...
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Stu...
SAN DIEGO--(BUSINESS WIRE)--Biocept provides on-campus COVID-19 testing to over 30 California community colleges, as students and staff return to in-person learning.
7 of the Best Penny Stocks to Buy Coming Into Year-End
These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared firs...
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to...
SAN DIEGO--(BUSINESS WIRE)--Biocept presents data showing ultra-sensitive Switch-Blocker technology detects rare cancer mutations at RAS-Targeted Drug Development Summit.